Global /Israel /Healthcare /Biotechnology /ENLV

Enlivex Ltd.

ENLV

• NASDAQ: ENLV • Delayed

0.8015USD -3%

As of 7 June 2026, Enlivex Ltd. has a market cap of $190.26M USD, ranking #21407 globally and #294 in Israel. It ranks #1919 in the Healthcare sector, and #372 in the Biotechnology industry.

Global Rank

21407

Country Rank

294

Sector Rank

1919

Industry Rank

372

Key Stats

Market Cap

$190.26MUSD

Enterprise Value

$185.08MUSD

EBITDA (TTM)

-$14.67MUSD

Net Income (TTM)

$1.24BUSD

PE Ratio

0.0

PB Ratio

0.1

Company Profile

Country (HQ)

Israel

Sector

Healthcare

Industry

Biotechnology

CEO

Oren Hershkovitz open_in_new

Employees

Founded

2005

IPO

12 Dec 1995

Website

enlivex.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3%	-8.9%	-24%	-30%	-26%	14%	-22%	-72%	-92%

News

ENLV Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	ENLV אנלייבקס תרפיוטיקס בע''מ ISIN: IL0011319527 Shares Out.: Shares Outstanding: 241.049M¹ Shares Float: 31.939M² TV: TradingView: NASDAQ: ENLV SA: Stock Analysis: NASDAQ: ENLV YF: Yahoo Finance: ENLV GF: Google Finance: NASDAQ: ENLV NQ: NASDAQ: ENLV BA: Barron's: ENLV MS: Morningstar: XNAS: ENLV	0.8015 USD	TV: TradingView: NASDAQ: ENLV SA: Stock Analysis: NASDAQ: ENLV YF: Yahoo Finance: ENLV GF: Google Finance: NASDAQ: ENLV NQ: NASDAQ: ENLV BA: Barron's: ENLV MS: Morningstar: XNAS: ENLV
Tel Aviv Stock Exchange (TLV) MIC: XTAE	ENLV אנלייבקס תרפיוטיקס בע''מ ISIN: IL0011319527 Shares Out.: Shares Outstanding: 237.381M¹ Shares Float: 31.453M² TV: TradingView: TASE: ENLV SA: Stock Analysis: TLV: ENLV YF: Yahoo Finance: ENLV.TA GF: Google Finance: TLV: ENLV BA: Barron's: ENLV MS: Morningstar: XTAE: ENLV	270 ILA	TV: TradingView: TASE: ENLV SA: Stock Analysis: TLV: ENLV YF: Yahoo Finance: ENLV.TA GF: Google Finance: TLV: ENLV BA: Barron's: ENLV MS: Morningstar: XTAE: ENLV

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Enlivex Ltd.

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

Similar Companies

Industry: Biotechnology (Israel)

Name	Market Cap (USD) diff.	PE	Country
Kamada Ltd. NASDAQ: KMDA	$470.55M 147%	23.3	Israel
Israel Canada Hotels Ltd. TLV: DNA	$332.67M 962.09M ILS 75%	267.3	Israel
Compugen Ltd. NASDAQ: CGEN	$245.84M 29%	6.9	Israel
Kadimastem Ltd. TLV: KDST	$55.69M 161.06M ILS -71%	-	Israel
Pluri Inc. NASDAQ: PLUR	$34.07M -82%	-	Israel
Polyrizon Ltd. NASDAQ: PLRZ	$28.03M -85%	-	Israel

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 96K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 84K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 25K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 23K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 23K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 22K%	37.2	Switzerland

chevron_leftBack